Equities
  • Price (MXN)2,817.11
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change+2.29%
  • Beta--
Data delayed at least 20 minutes, as of Mar 04 2022 10:30 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through DIS segment, which provides diagnostic information services to a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers, accountable care organizations (ACOs) and direct contract entities (DCEs). It is also engaged in two business operations, Diagnostic Information Services, which develops and delivers diagnostic information services that provides insights to a range of customers, and the Diagnostic Solutions group includes its risk assessment services business, which offers solutions for insurers and its healthcare information technology businesses, which offers solutions for healthcare providers. The Company’s services primarily are provided under the Quest Diagnostics brand, but it also provides services under other brands, including AmeriPath, Dermpath Diagnostics, ExamOne and Quanum.

  • Revenue in USD (TTM)10.68bn
  • Net income in USD1.87bn
  • Incorporated1996
  • Employees40.00k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
DGX:NYQ since
announced
Transaction
value
Pack Health LLCAnnounced18 Jan 202218 Jan 2022Announced-4.86%--
Labtech Diagnostics LLCDeal completed14 Dec 202114 Dec 2021Deal completed-17.07%--
Data delayed at least 15 minutes, as of May 16 2022 21:10 BST.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.